儿童镰状细胞病血管闭塞性疼痛发作镇痛趋势与医院实践差异:11年分析
该横断面分析利用美国34家儿童医院2013年1月1日至2023年12月31日的数据,分析86,111次儿童镰状细胞病血管闭塞发作急诊就诊的镇痛趋势与医院间差异。首次就诊当日阿片类使用率82%、NSAIDs 72%、对乙酰氨基酚17%、氯胺酮1%,NSAIDs与阿片类联用率59%。出院患者中NSAIDs使用(斜率1.68%/年,95%CI 0.91%, 2.45%)和NSAIDs-阿片类联用(斜率1.03%/年,95%CI 0.37%, 1.69%)呈正向趋势;住院患者中对乙酰氨基酚(斜率1.29%/年,95%CI 0.69%, 1.89%)和氯胺酮(斜率0.36%/年,95%CI 0.27%, 0.45%)显著上升,阿片类使用不变。大医院更可能使用阿片类但较少联用NSAIDs。医院间镇痛实践差异提示需标准化疼痛管理策略。
要点
- 86,111次儿童镰状细胞病血管闭塞发作急诊就诊中,阿片类使用率82%、NSAIDs 72%、对乙酰氨基酚17%、氯胺酮1%,NSAIDs与阿片类联用率59%。
- 出院患者NSAIDs使用呈正向趋势(斜率1.68%/年,95%CI 0.91%, 2.45%),NSAIDs-阿片类联用亦增加(斜率1.03%/年,95%CI 0.37%, 1.69%)。
- 住院患者中对乙酰氨基酚(斜率1.29%/年,95%CI 0.69%, 1.89%)和氯胺酮(斜率0.36%/年,95%CI 0.27%, 0.45%)显著上升,阿片类使用保持不变。
- 大医院比中等规模医院更可能使用阿片类,但较少联用NSAIDs与阿片类。
- 指南推荐常规联用NSAIDs与阿片类,但推荐基于低确定性证据。
适用人群与场景
- 2013年1月1日至2023年12月31日在美国34家儿童医院急诊科就诊的镰状细胞病血管闭塞发作患儿,共86,111次就诊。
研究设计与关键结果
- 研究类型:横断面研究,使用儿科健康信息系统数据,覆盖美国34家儿童医院,纳入2013年1月1日至2023年12月31日86,111次镰状细胞病血管闭塞发作急诊就诊。
- 主要结局为首次就诊第一个日历日给予阿片类、NSAIDs、对乙酰氨基酚和/或氯胺酮的就诊比例:阿片类82%、NSAIDs 72%、对乙酰氨基酚17%、氯胺酮1%。
- 次要结局NSAIDs与阿片类联用率59%。
- 出院患者中NSAIDs使用呈正向趋势(斜率1.68%/年,95%CI 0.91%, 2.45%),NSAIDs-阿片类联用呈正向趋势(斜率1.03%/年,95%CI 0.37%, 1.69%),对乙酰氨基酚使用增加(斜率0.99%/年,95%CI 0.80%, 1.17%)。
- 住院患者中对乙酰氨基酚显著上升(斜率1.29%/年,95%CI 0.69%, 1.89%),氯胺酮显著上升(斜率0.36%/年,95%CI 0.27%, 0.45%),阿片类使用保持不变。
- 观察到显著医院间差异:大医院比中等规模医院更可能使用阿片类,但较少联用NSAIDs与阿片类。
证据类型、等级与局限
- 证据类型:横断面分析。
- 指南推荐常规联用NSAIDs与阿片类,但推荐基于低确定性证据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 过去十年儿童镰状细胞病血管闭塞发作管理中NSAIDs、对乙酰氨基酚和氯胺酮使用增加,阿片类使用保持一致;NSAIDs与阿片类联用增加,反映指南依从性。
- 医院间镇痛实践差异提示需要标准化该人群的疼痛管理策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: This cross-sectional analysis of 86,111 visits for sickle cell disease and vaso-occlusive episodes (VOE) in U.S. pediatric emergency departments between 2013 and 2023 shows increased use of NSAIDs, ketamine, and acetaminophen, with unchanged opioid use. Hospitals with a higher volume of VOE visits more frequently administered opioids.
BACKGROUND: Vaso-occlusive episodes (VOEs) are a hallmark of sickle cell disease (SCD), leading to frequent emergency department (ED) visits. Effective pain management is crucial, with guidelines recommending routine use of non-steroidal anti-inflammatory drugs (NSAIDs) with opioids, and emerging evidence supporting ketamine use. However, these recommendations are based on low-certainty evidence, and the impact of these guidelines on analgesia use over time remains unclear.
OBJECTIVE: This study aimed to analyze trends in analgesia use over an 11-year period in pediatric SCD patients presenting to U.S. EDs with VOE and assess variations in treatment across hospitals.
METHODS: A cross-sectional study was conducted using data from the Pediatric Health Information System covering 34 U.S. children's hospitals from January 1, 2013, to December 31, 2023. The primary outcomes were the proportions of visits where opioids, NSAIDs, acetaminophen, and/or ketamine were administered on the first calendar day of the initial visit. Secondary outcomes included the co-administration of NSAIDs with opioids. Logistic and linear regression models were used to assess trends and hospital-level variations.
RESULTS: A total of 86,111 ED visits for VOE were analyzed. Opioids were administered in 82 % of encounters, NSAIDs in 72 %, acetaminophen in 17 %, and ketamine in 1 %. Co-administration of NSAIDs with opioids occurred in 59 % of the visits. Among discharged patients, there was a positive trend for NSAID use (slope: 1.68 %/year, 95 % CI: 0.91 %, 2.45 %) and NSAID-opioid co-administration (slope: 1.03 %/year, 95 % CI: 0.37 %, 1.69 %) over time. Acetaminophen use also increased over the study period (slope: 0.99 %/year, 95 % CI: 0.80 %, 1.17 %). In hospitalized patients, there was a significant upward trend for acetaminophen (slope: 1.29 %/year, 95 % CI: 0.69 %, 1.89 %) and ketamine (slope: 0.36 %/year, 95 % CI: 0.27 %, 0.45 %), while opioid use remained unchanged. Significant hospital-level variations were observed, with larger hospitals more likely to administer opioids but less likely to co-administer NSAIDs with opioids compared to medium-volume hospitals.
CONCLUSION: Over the past decade, the use of NSAIDs, acetaminophen, and ketamine has increased in the management of VOE in pediatric SCD patients, while opioid use remains consistent. The co-administration of NSAIDs and opioids has also increased, reflecting guideline adherence. Variations in analgesia practices across hospitals underscore the need for standardizing pain management strategies in this population.
参考来源
- Eltorki M, Hall M, Ramgopal S, et al. Trends and hospital practice variation for analgesia for children with sickle cell disease with vaso-occlusive pain episodes: An 11-year analysis. Am J Emerg Med. 2024. PMID: 39427500. doi:10.1016/j.ajem.2024.10.028
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。